UCFA
TSRX

United Capital Financial Advisors’s TRIUS THERAPEUTICS INC COM STK (DE) TSRX Stock Holding History

United Capital Financial Advisors’s Portfolio TSRX Stock Details TSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-59,790
Closed -$484K – 789
2013
Q2 		$484K Buy
+59,790
New +$442K 0.01% 511

Other funds holding TSRX

PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

United Capital Financial Advisors's TSRX Position: Q3 2013 in Review

United Capital Financial Advisors sold out of TRIUS THERAPEUTICS INC COM STK (DE) (TSRX) in Q3 2013, closing a stake of 59,790 shares — an estimated $484K sold.

United Capital Financial Advisors first reported a position in TSRX in Q2 2013 and held it in 1 quarter. The position peaked at $484K in Q2 2013. 7 funds tracked by Wall St. Rank hold TSRX as of Q3 2013.

  • United Capital Financial Advisors reported no remaining TRIUS THERAPEUTICS INC COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • United Capital Financial Advisors sold 59,790 TRIUS THERAPEUTICS INC COM STK (DE) shares in Q3 2013, an estimated $484K.
  • United Capital Financial Advisors first reported a position in TRIUS THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • United Capital Financial Advisors's TRIUS THERAPEUTICS INC COM STK (DE) position peaked at $484K in Q2 2013.
  • 7 funds tracked by Wall St. Rank held TRIUS THERAPEUTICS INC COM STK (DE) as of Q3 2013.

Based on United Capital Financial Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.